Race and Sex Impact Treatment in Newly Diagnosed A-Fib

This article originally appeared here.
Share this content:
Race and Sex Impact Treatment in Newly Diagnosed A-Fib
Race and Sex Impact Treatment in Newly Diagnosed A-Fib

WEDNESDAY, July 1, 2015 (HealthDay News) -- For patients newly diagnosed with atrial fibrillation (AF), race and sex may affect treatment, according to a study published in the July issue of Heart Rhythm.

Prashant D. Bhave, M.D., from the University of Iowa Hospitals and Clinics in Iowa City, and colleagues used administrative encounter data for Medicare beneficiaries to identify patients with newly diagnosed AF; 517,941 patients met the study criteria (87 percent white, 7 percent black, and 6 percent Hispanic; 41 percent male). The authors catalogued services received after initial AF diagnosis.

The researchers observed statistically significant differences in AF-related service use by race and sex, in multivariate analysis, with white patients and male patients receiving the most care. The most pronounced disparities were observed for catheter ablation (Hispanic versus white: adjusted hazard ratio [aHR], 0.70; female versus male: aHR, 0.65; both P < 0.001) and oral anticoagulation receipt (black versus white: aHR, 0.94; Hispanic versus white: aHR, 0.94; male versus female, aHR, 0.93; all P < 0.001)

"Identifying patterns of disparity and barriers to care at the regional and local level may help to guide community-based interventions," the authors write. "Strategies to educate patients, change patterns of referral, and improve access to specialist care for women and minorities with AF may help to improve quality of life and cardiovascular outcomes in those patients."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »